Elsevier

Blood Reviews

Volume 32, Issue 3, May 2018, Pages 225-234
Blood Reviews

Review
Clinical, laboratory and imaging findings in Castleman's disease – The subtype decides

https://doi.org/10.1016/j.blre.2017.11.005Get rights and content

Abstract

Castleman's disease (CD) is a rare lymphoproliferative disorder with its distinct unicentric (uCD) and multicentric (mCD) entities. The present work aimed at characterizing CD in more detail. From the 775 articles found by a PubMed search, 1133 cases were extracted. Two own cases were included. UCD was identified in 719 (42% males) and mCD in 416 (63% males) cases. Age in uCD was 34 ± 17 and in mCD 48 ± 18 years. The hyaline-vascular type predominated in uCD and the plasma cell type in mCD. Clinical symptoms were more common in mCD. The head and neck region was most frequently affected in uCD and the axillary region in mCD. Prevalence of human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) positivity was higher in mCD. In CT scans, high contrast enhancement and calcifications were more frequent in uCD (all p < 0.0001).

The two forms of CD not only differ markedly in their clinical, laboratory and imaging findings, but also in treatment response and prognosis.

Introduction

Castleman's disease (CD) is a rare heterogenous lymphoproliferative disorder of unknown etiopathogenesis causing non-neoplastic lymphadenopathy. The disease was first described by Castleman et al. in 1956 as a large thymoma-like mass in the anterior mediastinum and later classified in a series of thirteen patients with unicentric localization [1]. In addition to the unicentric form of CD (uCD), Gaba et al. described in 1972 a disseminated or multicentric form of CD (mCD) [2]. This systemic disease is frequently associated with a general immunosuppression, and human herpesvirus-8 (HHV-8) or human immunodeficiency virus (HIV) infection [3]. Histopathologically, three forms can be discriminated: the hyaline vascular, the plasma cell-rich form, and a mixed variant [4].

In uCD, the hyaline-vascular type is known to be with almost 90% of cases the most predominant type, affecting mostly younger patients without a preference in sex. The mediastinum, the abdomen and the axillary and cervical lymph node regions are reported as the most common manifestations [5], [6]. But rare extranodal sites, such as larynx as well as intramuscular, subcutaneous, and intracranial locations, have been described additionally [7]. This form of CD is frequently asymptomatic and often accidentally discovered as a part of a chest X-ray [8], [9]. Laboratory alterations can be found only sporadically [10].

In contrast, mCD is a systemic disease [10], occurring in both an aggressive and a chronic persistent or chronic relapsing course. This form is considered to be a potentially malignant lymphoproliferative disease which may associate with the POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal-proteinaemia, skin changes) syndrome (11–30% of the patients with CD) [11], with HIV infection (estimated incidence in HIV-1 patients 2.3 per 10,000 patient-years in the pre-combination antiretroviral therapy (cART) era prior to 1996, and 8.3 per 10,000 patient-years since 2000) [12], with Kaposi's sarcoma (13% of HIV-negative patients with mCD up to 75% of HIV-positive patients with mCD [31]), or rarely with lymphoma (predominantly B-cell non-Hodgkin's lymphoma (B-NHL) with 71% of all reported cases of association CD-NHL) [13]. In most cases of mCD, histologically the plasma cell type is found. In general, elderly patients are more often affected by the multicentric form.

Though symptoms and laboratory findings vary depending on the variant of disease, both forms are related to an increased release of cytokines. Especially interleukin 6 (IL-6) is closely linked to the activity of the disease [14], [15]. A decrease in symptoms is always associated with a reduction in IL-6 levels, and vice versa [16].

The present work was intended to contribute to a better understanding of the rare and often unknown clinical picture of CD, paying special attention to the differences between the uCD and mCD. Improved knowledge on the signs and symptoms as well as laboratory and imaging findings of CD may accelerate its diagnosis and may enable an earlier adequate treatment.

Section snippets

Search strategy in MEDLINE and selection criteria for analysis

A MEDLINE search using the keyword “Castleman's disease” was conducted. Articles published until September 2011 were limited on German, English, French, and Italian language. For the current analysis, only case reports and case series were considered. Of 1799 articles retrieved, a total of 775 articles fulfilling these criteria were found. From these publications, a total 1133 cases were extracted for further analysis. From our own University Hospital two so far unpublished cases of CD were

Results

As shown in Fig. 1, we analyzed 1135 cases of CD which included two so far unpublished cases from our own facility. UCD was described in 719 patients and mCD in 416 patients.

Discussion

The present study aimed at characterizing in more detail the clinical, laboratory, radiological and therapeutic findings of the rare disorder CD paying special attention to the differences between its two variants, the unicentric and the multicentric forms. Until now, commonly case reports and studies with a limited number of patients reported on the typical characteristics of both forms of CD. In this work, 1135 case presentations of patients with CD including our own two so far unpublished

Practice points

  • Clinical signs and symptoms as well as laboratory alterations are rare in uCD, but frequent in mCD, underlining its systemic nature.

  • Histologically, the two forms of CD significantly differ, with predominance of the hyaline-vascular type in uCD and predominance of the plasma cell type and two-fold higher frequency of the mixed type in mCD.

  • In uCD, the head and neck region is the most affected localization followed by the retroperitoneal space, whereas in mCD, axillary and abdominal manifestations

Research agenda

  • A uniform therapy of mCD is not available and treatment recommendations are currently based on case reports, case series and a limited number of clinical trials.

  • In light of the rarity of disease, large-scale randomized controlled trials will not be feasible. However, implementation of a registry of this rare disease may allow subtype-specific treatment recommendations in the future.

Conflict of interests

The authors have no relevant conflicts to disclose.

References (93)

  • E. Oksenhendler et al.

    High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease

    Blood

    (2002)
  • E. Oksenhendler et al.

    High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients

    Blood

    (2000)
  • L. Giffin et al.

    KSHV: pathways to tumorigenesis and persistent infection

    Adv Virus Res

    (2014)
  • A.E. Grulich et al.

    Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

    Lancet

    (2007)
  • E. Peralbo et al.

    NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing

    Exp Gerontol

    (2007)
  • L. Wen et al.

    CT characteristics of cervical Castleman's disease

    Clin Imaging

    (2005)
  • J.C. Hillier et al.

    Imaging features of multicentric Castleman's disease in HIV infection

    Clin Radiol

    (2004)
  • L.M. Germaine et al.

    Castleman's disease

    Clin Imaging

    (2003)
  • R. Madan et al.

    The spectrum of Castleman's disease: mimics, radiologic pathologic correlation and role of imaging in patient management

    Eur J Radiol

    (2012)
  • L. Friedman et al.

    Computerized tomography of Castleman's disease simulating a false renal artery aneurysm: a case report

    J Urol

    (1987)
  • X.H. Jiang et al.

    Castleman disease of the neck: CT and MR imaging findings

    Eur J Radiol

    (2014)
  • S. Wang et al.

    Clinicopathological characteristics of unicentric retroperitoneal Castleman's disease: a study of 14 cases

    World J Surg Oncol

    (2016)
  • C.Y. Lin et al.

    Castleman's disease in the head and neck region: meta-analysis of reported cases in Taiwan and literature review

    J Formos Med Assoc

    (2010)
  • N. Dupin et al.

    HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma

    Blood

    (2000)
  • N. Nishimoto et al.

    Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

    Blood

    (2005)
  • F. van Rhee et al.

    Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

    Lancet Oncol

    (2014)
  • L. Yu et al.

    Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease

    Blood

    (2017)
  • B. Castleman et al.

    Localized mediastinal lymphnode hyperplasia resembling thymoma

    Cancer

    (1956)
  • A.R. Gaba et al.

    Multicentric giant lymph node hyperplasia

    Am J Clin Pathol

    (1978)
  • A.Y. Liu et al.

    Idiopathic multicentric Castleman's disease: a systematic literature review

    Lancet Haematol

    (2016)
  • A.R. Keller et al.

    Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations

    Cancer

    (1972)
  • B. Bleiber et al.

    Castleman disease

    Med Klin (Munich)

    (2000)
  • B. Roca

    Castleman's disease. A review

    AIDS Rev

    (2009)
  • H. Schwarzenberg et al.

    Castleman's disease: evaluation of 338 cases

    Rofo

    (1995)
  • M. Michaelides et al.

    Posterior mediastinal Castleman's disease presented as hypervascular lipomatous tumor

    Hippokratia

    (2011)
  • C. Spedini et al.

    Castleman's disease presenting as an asymptomatic solitary pulmonary nodule

    Monaldi Arch Chest Dis

    (1995)
  • B. Ye et al.

    A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients

    Med Oncol

    (2010)
  • C. Larroche et al.

    Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review

    Am J Hematol

    (2002)
  • G. Frizzera

    Castleman's disease and related disorders

    Semin Diagn Pathol

    (1988)
  • C.E. Cervantes et al.

    Castleman disease: a rare condition with endocrine manifestations

    Cureus

    (2015)
  • Y. Dong et al.

    Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center

    Leuk Lymphoma

    (2009)
  • S. Guillet et al.

    Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution

    Am J Hematol

    (2016)
  • A. Ray et al.

    Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome

    J Infect Dis

    (2012)
  • G. Venkataraman et al.

    Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

    Am J Clin Pathol

    (2013)
  • F. van Rhee et al.

    Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy

    Clin Adv Hematol Oncol

    (2010)
  • A.P.O.E.M.S. Dispenzieri

    Syndrome: update on diagnosis, risk-stratification, and management

    Am J Hematol

    (2015)
  • Cited by (32)

    View all citing articles on Scopus
    1

    Both authors contributed equally.

    View full text